Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4105933 Target Snapshot

Uncharacterized protein FLJ45252 · SINGLE PROTEIN · Homo sapiens

244Compounds
2Assays
16Approved Drugs
244.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q6ZSR9. Use UniProt Q6ZSR9 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q6ZSR9 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Uncharacterized protein FLJ45252 as ChEMBL target CHEMBL4105933, mapped to UniProt Q6ZSR9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Uncharacterized protein FLJ45252
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4105933
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q6ZSR9
Uncharacterized protein FLJ45252
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Uncharacterized protein FLJ45252 is the right protein anchor across sources, using UniProt Q6ZSR9 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelUncharacterized protein FLJ45252
UniProt AccessionQ6ZSR9
Component TypeProtein
Sequence Length355 aa

Uncharacterized protein FLJ45252

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Uncharacterized protein FLJ45252, mapped to UniProt Q6ZSR9. Sequence length is 355 aa.

Mapped IDQ6ZSR9
Review nameUncharacterized protein FLJ45252
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

16
Approved
4
Phase III
12
Phase II
15
Phase I
Assay Mix

Activity Type Distribution

KD244.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5653589 9.68 Kd 0.21 Preclinical
CHEMBL3991929 9.15 Kd 0.7 Preclinical
CHEMBL3545137 8.7 Kd 2.0 Preclinical
CHEMBL1078178 8.52 Kd 3.0 Approved
CHEMBL482967 8.15 Kd 7.0 Preclinical
CHEMBL3545328 8.15 Kd 7.0 Preclinical
CHEMBL4289017 8.0 Kd 10.0 Preclinical
CHEMBL3301622 7.96 Kd 11.0 Approved
CHEMBL1667969 7.89 Kd 13.0 Clinical
CHEMBL281948 7.68 Kd 21.0 Preclinical
Distribution

pChEMBL Value Distribution

4
5.0
13
5.5
8
6.0
10
6.5
5
7.0
5
7.5
3
8.0
2
8.5
1
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
PACRITINIB
CHEMBL2035187
Approved 2022
SELUMETINIB
CHEMBL1614701
Approved 2020
FEDRATINIB
CHEMBL1287853
Approved 2019
GILTERITINIB
CHEMBL3301622
Approved 2018
BARICITINIB
CHEMBL2105759
Approved 2017
ABEMACICLIB
CHEMBL3301610
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

2
Total Assays
53
Tested Compounds
1
Assay Types
Binding — 2 assays, 53 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 2 8.2
subcellular format 1 51 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine